fda drug safety communication semaglutide naion 2025 The obesity (Wegovy) conferred a significantly higher risk of ischemic optic neuropathy (ION) than any other GLP-1 agonist, including semaglutide for diabetes (Ozempic), an analysis of data showed. Added Addressing patient concerns about the

Semaglutide is a GLP-1 receptor agonist medication designed to regulate appetite and hunger

Even on schedule, real-world pharmacy availability typically lags approval by 3090 days as supply ramps

Rotate specific injection points within the inner thigh to avoid lipohypertrophy

TRT Nation's supply source and formulation may differ from branded versions but efficacy profile is comparable

[DOI] [PMC free article] [PubMed] [Google Scholar] 554.Khoshnoodi MA, Truelove S, Burakgazi A, et al

Significant weight loss typically occurs over several months, with most patients reaching their peak weight loss between 6 to 12 months of consistent treatment